Log in to search using one of your social media accounts:

 

Management of Advanced and Relapsed/Refractory Extra-Nodal Natural Killer T-Cell Lymphoma (ENKL): An Analysis of Stem Cell Transplant and Chemotherapy Outcomes

Extra-nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year.1, 2 ENKL is universally associated with Epstein-Barr virus (EBV) infection, and is more frequent in Asian, Central American and South American populations, where it constitutes 5-15% of all lymphomas.3-5 Patients with advanced stage ENKL (stage III-IV) and relapsed/refractory early stage disease are treated with systemic chemotherapy with or without radiotherapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Donghee Kim, Hee-Sook Jun
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
James S. Lawson, Brian Salmons, Wendy K. Glenn
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Laura A. Michielsen, Kevin Budding, Dani ël Drop, Ed A. van de Graaf, Tineke Kardol-Hoefnagel, Marianne C. Verhaar, Arjan D. van Zuilen, Henny G. Otten
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. Micro-Abstract We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our res...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions PET/CT compared to CECT allowed a more accurate staging and after therapy pointed out minimal residual disease in 22% of CECT negative pts and complete remission in 36% of CECT positive pts.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: MTA I: Leukemia/Lymphoma/Myeloma Posters Source Type: research
Conclusion Most PTCL relapses were detected before planned SI, and most patients had symptoms with relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse, suggesting a limited utility of routine imaging for detecting PTCL relapses. Micro-Abstract Data from aggressive lymphoma such as diffuse large B-cell lymphoma and Hodgkin lymphoma suggest a limited utility of surveillance imaging (SI) after achieving first complete remission. The present study of patients with peripheral T-cell lymphoma showed similar data, with most relapses detected apart from planned SI and associated with abnormal symptoms or signs...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions The majority of PTCL relapses were detected prior to planned SI and most patients had symptoms on relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse suggesting a limited utility of routine imaging in detecting PTCL relapses. Teaser Data from aggressive lymphoma such as diffuse large B-cell lymphoma and Hodgkin lymphoma suggest a limited utility of surveillance imaging (SI) after achieving first complete remission. This study in patients with peripheral T-cell lymphoma (PTCL) is similar in that it showed that most relapses are detected apart from planned SI and are associated with abnormal s...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion SS is a rare and aggressive type of CTCL that is refractory to current therapies. We report that CRs can be achieved in 3 methods: combined immunomodulatory therapy, targeted biologic agents, or total skin electron beams followed by nonablative allogeneic SCT. Micro-Abstract Sézary syndrome is a rare leukemic variant of primary cutaneous non-Hodgkin lymphomas that is difficult to treat. We report on 18 patients who had achieved long-term complete remission or response (CR) of ≥ 1 year and 7 patients who had achieved durable responses (DR) with subsequent relapse. The choices of therapy, including...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | T-cell Lymphoma | Transplants | USA Health